

Europe Pharmacogenomics Market (2019-2025)

<https://marketpublishers.com/r/EA9F8A93B28EN.html>

Date: June 2019

Pages: 103

Price: US\$ 1,500.00 (Single User License)

ID: EA9F8A93B28EN

Abstracts

The Europe Pharmacogenomics Market would witness market growth of 8.4% CAGR during the forecast period (2019–2025).

Pharmacogenomics is expected to facilitate the treatment of a wide spectrum of diseases such as cardiovascular diseases, Alzheimer disease, HIV/AIDS, and cancer among others. An upsurge in the investments for technology advancements is primarily poised to revolutionize the pharmacogenomics market. Furthermore, it also supports the customization of medicine doses according to a person's genetics. This, in turn, has led to an expansion of the market presence of pharmacogenomics throughout the healthcare sector.

Improved infrastructure and technological edge in comparison to other medical centers, the advent of highly skilled medical professionals, and patients preferring hospitals over others has propelled the growth of hospitals in the end user and is anticipated to be at the top throughout the pharmacogenomics market forecast. Furthermore, research institutions are the fastest growing in the end user segment owing to the robust use of pharmacogenomics as a tool for personalized drugs for curing diseases such as cancer, several infectious diseases like tuberculosis, HIV/AIDS and others.

Based on Technology, the market is segmented into Sequencing, Polymerase Chain Reaction, Electrophoresis, Mass Spectrometry, Microarray and Others. Based on Application, the market is segmented into Oncology, Psychiatry, Infectious Diseases, Neurological Diseases, Pain management, Cardiovascular Diseases and Others. Based on End User, the market is segmented into Hospitals and Clinics, Research Institutions, and Academic Institutes. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

The market research report covers the analysis of key stake holders of the market. Key

companies profiled in the report include Abbott Laboratories, Empire Genomics LLC, Illumina, Inc., oneome LLC, Myriad Genetics Inc., Thermo Fisher Scientific, Inc., Teva Pharmaceuticals Industries Ltd., Bayer AG, Opko Health, Inc., and Becton, Dickinson and Company.

Scope of the Study

Market Segmentation:

By Application

Sequencing

Polymerase Chain Reaction

Electrophoresis

Mass Spectrometry

Microarray

Others

By Application

Oncology

Psychiatry

Infectious Diseases

Neurological Diseases

Pain management

Cardiovascular Diseases

Others

By End User

Hospitals and Clinics

Research Institutions

Academic Institutes

By Country

Germany

UK

France

Russia

Spain

Italy

Rest of Europe

Companies Profiled

Abbott Laboratories

Empire Genomics LLC

Illumina, Inc.

Oneome LLC

Myriad Genetics Inc.

Thermo Fisher Scientific, Inc.

Teva Pharmaceuticals Industries Ltd.

Bayer AG

Opko Health, Inc.

Becton, Dickinson and Company

Contents

CHAPTER 1. MARKET SCOPE & METHODOLOGY

- 1.1 Market Definition
- 1.2 Objectives
- 1.3 Market Scope
- 1.4 Segmentation
 - 1.4.1 Europe Pharmacogenomics Market, by Application
 - 1.4.2 Europe Pharmacogenomics Market, by Application
 - 1.4.3 Europe Pharmacogenomics Market, by End User
 - 1.4.4 Europe Pharmacogenomics Market, by Country
- 1.5 Methodology for the research

CHAPTER 2. MARKET OVERVIEW

- 2.1 Introduction
 - 2.1.1 Overview
 - 2.1.2 Market Composition and Scenario
- 2.2 Key Factors Impacting the Market
 - 2.2.1 Market Drivers
 - 2.2.2 Market Restraints

CHAPTER 3. EUROPE PHARMACOGENOMICS MARKET BY TECHNOLOGY

- 3.1.1 Europe Sequencing Market by Country
- 3.1.2 Europe Polymerase Chain Reaction Market by Country
- 3.1.3 Europe Electrophoresis Market by Country
- 3.1.4 Europe Mass Spectrometry Market by Country
- 3.1.5 Europe Microarray Market by Country
- 3.1.6 Europe Others Market by Country

CHAPTER 4. EUROPE PHARMACOGENOMICS MARKET BY APPLICATION

- 4.1.1 Europe Oncology Market by Country
- 4.1.2 Europe Psychiatry Market by Country
- 4.1.3 Europe Infectious Diseases Market by Country
- 4.1.4 Europe Neurological Diseases Market by Country
- 4.1.5 Europe Pain Management Market by Country

4.1.6 Europe Cardiovascular Diseases Market by Country

4.1.7 Europe Others Market by Country

CHAPTER 5. EUROPE PHARMACOGENOMICS MARKET BY END USER

5.1.1 Europe Hospitals and Clinics Market by Country

5.1.2 Europe Research Institutions Market by Country

5.1.3 Europe Academic Institutes Market by Country

CHAPTER 6. EUROPE PHARMACOGENOMICS MARKET BY COUNTRY

6.1 Germany Pharmacogenomics Market

6.1.1 Germany Pharmacogenomics Market by Technology

6.1.2 Germany Pharmacogenomics Market by Application

6.1.3 Germany Pharmacogenomics Market by End User

6.2 UK Pharmacogenomics Market

6.2.1 UK Pharmacogenomics Market by Technology

6.2.2 UK Pharmacogenomics Market by Application

6.2.3 UK Pharmacogenomics Market by End User

6.3 France Pharmacogenomics Market

6.3.1 France Pharmacogenomics Market by Technology

6.3.2 France Pharmacogenomics Market by Application

6.3.3 France Pharmacogenomics Market by End User

6.4 Russia Pharmacogenomics Market

6.4.1 Russia Pharmacogenomics Market by Technology

6.4.2 Russia Pharmacogenomics Market by Application

6.4.3 Russia Pharmacogenomics Market by End User

6.5 Spain Pharmacogenomics Market

6.5.1 Spain Pharmacogenomics Market by Technology

6.5.2 Spain Pharmacogenomics Market by Application

6.5.3 Spain Pharmacogenomics Market by End User

6.6 Italy Pharmacogenomics Market

6.6.1 Italy Pharmacogenomics Market by Technology

6.6.2 Italy Pharmacogenomics Market by Application

6.6.3 Italy Pharmacogenomics Market by End User

6.7 Rest of Europe Pharmacogenomics Market

6.7.1 Rest of Europe Pharmacogenomics Market by Technology

6.7.2 Rest of Europe Pharmacogenomics Market by Application

6.7.3 Rest of Europe Pharmacogenomics Market by End User

CHAPTER 7. COMPANY PROFILES

7.1 ABBOTT Laboratories

7.1.1 Company Overview

7.1.2 Financial Analysis

7.1.3 Segmental and Regional Analysis

7.1.4 Research & Development Expense

7.1.5 Recent strategies and developments:

7.1.5.1 Collaborations, partnerships and agreements:

7.1.5.2 Product launches:

7.1.5.3 Acquisition and mergers:

7.1.6 SWOT Analysis

7.2 Empire Genomics LLC

7.2.1 Company Overview

7.3 Illumina, Inc.

7.3.1 Company Overview

7.3.2 Financial Analysis

7.3.3 Regional& Segmental Analysis

7.3.4 Research& Development Expenses

7.3.5 Recent strategies and developments:

7.3.5.1 Collaborations, partnerships and agreements:

7.3.5.2 Product launches:

7.3.5.3 Acquisition and mergers:

7.4 OneOme LLC

7.4.1 Company Overview

7.5 Myriad Genetics Inc.

7.5.1 Company Overview

7.5.2 Financial Analysis

7.5.3 Segmental and Regional Analysis

7.5.4 Research & Development Expense

7.5.5 Recent strategies and developments:

7.5.5.1 Collaborations, partnerships and agreements:

7.5.5.2 Product launches:

7.6 Thermo Fischer Scientific, Inc.

7.6.1 Company Overview

7.6.2 Financial Analysis

7.6.3 Segmental and Regional Analysis

7.6.4 Research & Development Expense

7.6.5 Recent strategies and developments:

7.6.5.1 Collaborations, partnerships and agreements:

7.6.5.2 Acquisition and mergers:

7.6.6 SWOT Analysis

7.7 Teva Pharmaceuticals Industries Ltd.

7.7.1 Company Overview

7.7.2 Financial Analysis

7.7.3 Segmental Analysis

7.7.4 Research & Development Expense

7.7.5 Recent strategies and developments:

7.7.5.1 Product launches:

7.8 Bayer AG

7.8.1 Company Overview

7.8.2 Financial Analysis

7.8.3 Segmental and Regional Analysis

7.8.4 Research & Development Expense

7.8.5 Recent strategies and developments:

7.8.5.1 Collaborations, partnerships and agreements:

7.8.6 SWOT Analysis

7.9 Opko Health, Inc. (GeneDx, Inc.)

7.9.1 Company Overview

7.9.2 Financial Analysis

7.9.3 Research & Development Expense

7.9.4 Recent strategies and developments:

7.9.4.1 Collaborations, partnerships and agreements:

7.9.4.2 Product launches:

7.1 Becton, Dickinson and Company

7.10.1 Company Overview

7.10.2 Financial Analysis

7.10.3 Segmental and Regional Analysis

7.10.4 Research & Development Expense

7.10.5 Recent strategies and developments:

7.10.5.1 Collaborations, partnerships and agreements:

7.10.5.2 Acquisition and mergers:

7.10.5.3 Product launches:

7.10.6 SWOT Analysis

List Of Tables

LIST OF TABLES

TABLE 1 EUROPE PHARMACOGENOMICS MARKET, 2015 - 2018, USD MILLION

TABLE 2 EUROPE PHARMACOGENOMICS MARKET, 2019 - 2025, USD MILLION

TABLE 3 EUROPE PHARMACOGENOMICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION

TABLE 4 EUROPE PHARMACOGENOMICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION

TABLE 5 EUROPE SEQUENCING MARKET BY COUNTRY, 2015 - 2018, USD MILLION

TABLE 6 EUROPE SEQUENCING MARKET BY COUNTRY, 2019 - 2025, USD MILLION

TABLE 7 EUROPE POLYMERASE CHAIN REACTION MARKET BY COUNTRY, 2015 - 2018, USD MILLION

TABLE 8 EUROPE POLYMERASE CHAIN REACTION MARKET BY COUNTRY, 2019 - 2025, USD MILLION

TABLE 9 EUROPE ELECTROPHORESIS MARKET BY COUNTRY, 2015 - 2018, USD MILLION

TABLE 10 EUROPE ELECTROPHORESIS MARKET BY COUNTRY, 2019 - 2025, USD MILLION

TABLE 11 EUROPE MASS SPECTROMETRY MARKET BY COUNTRY, 2015 - 2018, USD MILLION

TABLE 12 EUROPE MASS SPECTROMETRY MARKET BY COUNTRY, 2019 - 2025, USD MILLION

TABLE 13 EUROPE MICROARRAY MARKET BY COUNTRY, 2015 - 2018, USD MILLION

TABLE 14 EUROPE MICROARRAY MARKET BY COUNTRY, 2019 - 2025, USD MILLION

TABLE 15 EUROPE OTHERS MARKET BY COUNTRY, 2015 - 2018, USD MILLION

TABLE 16 EUROPE OTHERS MARKET BY COUNTRY, 2019 - 2025, USD MILLION

TABLE 17 EUROPE PHARMACOGENOMICS MARKET BY APPLICATION, 2015 - 2018, USD MILLION

TABLE 18 EUROPE PHARMACOGENOMICS MARKET BY APPLICATION, 2019 - 2025, USD MILLION

TABLE 19 EUROPE ONCOLOGY MARKET BY COUNTRY, 2015 - 2018, USD MILLION

TABLE 20 EUROPE ONCOLOGY MARKET BY COUNTRY, 2019 - 2025, USD

MILLION

TABLE 21 EUROPE PSYCHIATRY MARKET BY COUNTRY, 2015 - 2018, USD
MILLION

TABLE 22 EUROPE PSYCHIATRY MARKET BY COUNTRY, 2019 - 2025, USD
MILLION

TABLE 23 EUROPE INFECTIOUS DISEASES MARKET BY COUNTRY, 2015 - 2018,
USD MILLION

TABLE 24 EUROPE INFECTIOUS DISEASES MARKET BY COUNTRY, 2019 - 2025,
USD MILLION

TABLE 25 EUROPE NEUROLOGICAL DISEASES MARKET BY COUNTRY, 2015 -
2018, USD MILLION

TABLE 26 EUROPE NEUROLOGICAL DISEASES MARKET BY COUNTRY, 2019 -
2025, USD MILLION

TABLE 27 EUROPE PAIN MANAGEMENT MARKET BY COUNTRY, 2015 - 2018, USD
MILLION

TABLE 28 EUROPE PAIN MANAGEMENT MARKET BY COUNTRY, 2019 - 2025, USD
MILLION

TABLE 29 EUROPE CARDIOVASCULAR DISEASES MARKET BY COUNTRY, 2015 -
2018, USD MILLION

TABLE 30 EUROPE CARDIOVASCULAR DISEASES MARKET BY COUNTRY, 2019 -
2025, USD MILLION

TABLE 31 EUROPE OTHERS MARKET BY COUNTRY, 2015 - 2018, USD MILLION

TABLE 32 EUROPE OTHERS MARKET BY COUNTRY, 2019 - 2025, USD MILLION

TABLE 33 EUROPE PHARMACOGENOMICS MARKET BY END USER, 2015 - 2018,
USD MILLION

TABLE 34 EUROPE PHARMACOGENOMICS MARKET BY END USER, 2019 - 2025,
USD MILLION

TABLE 35 EUROPE HOSPITALS AND CLINICS MARKET BY COUNTRY, 2015 -
2018, USD MILLION

TABLE 36 EUROPE HOSPITALS AND CLINICS MARKET BY COUNTRY, 2019 -
2025, USD MILLION

TABLE 37 EUROPE RESEARCH INSTITUTIONS MARKET BY COUNTRY, 2015 -
2018, USD MILLION

TABLE 38 EUROPE RESEARCH INSTITUTIONS MARKET BY COUNTRY, 2019 -
2025, USD MILLION

TABLE 39 EUROPE ACADEMIC INSTITUTES MARKET BY COUNTRY, 2015 - 2018,
USD MILLION

TABLE 40 EUROPE ACADEMIC INSTITUTES MARKET BY COUNTRY, 2019 - 2025,
USD MILLION

TABLE 41 EUROPE PHARMACOGENOMICS MARKET BY COUNTRY, 2015 - 2018, USD MILLION

TABLE 42 EUROPE PHARMACOGENOMICS MARKET BY COUNTRY, 2019 - 2025, USD MILLION

TABLE 43 GERMANY PHARMACOGENOMICS MARKET, 2015 - 2018, USD MILLION

TABLE 44 GERMANY PHARMACOGENOMICS MARKET, 2019 - 2025, USD MILLION

TABLE 45 GERMANY PHARMACOGENOMICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION

TABLE 46 GERMANY PHARMACOGENOMICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION

TABLE 47 GERMANY PHARMACOGENOMICS MARKET BY APPLICATION, 2015 - 2018, USD MILLION

TABLE 48 GERMANY PHARMACOGENOMICS MARKET BY APPLICATION, 2019 - 2025, USD MILLION

TABLE 49 GERMANY PHARMACOGENOMICS MARKET BY END USER, 2015 - 2018, USD MILLION

TABLE 50 GERMANY PHARMACOGENOMICS MARKET BY END USER, 2019 - 2025, USD MILLION

TABLE 51 UK PHARMACOGENOMICS MARKET, 2015 - 2018, USD MILLION

TABLE 52 UK PHARMACOGENOMICS MARKET, 2019 - 2025, USD MILLION

TABLE 53 UK PHARMACOGENOMICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION

TABLE 54 UK PHARMACOGENOMICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION

TABLE 55 UK PHARMACOGENOMICS MARKET BY APPLICATION, 2015 - 2018, USD MILLION

TABLE 56 UK PHARMACOGENOMICS MARKET BY APPLICATION, 2019 - 2025, USD MILLION

TABLE 57 UK PHARMACOGENOMICS MARKET BY END USER, 2015 - 2018, USD MILLION

TABLE 58 UK PHARMACOGENOMICS MARKET BY END USER, 2019 - 2025, USD MILLION

TABLE 59 FRANCE PHARMACOGENOMICS MARKET, 2015 - 2018, USD MILLION

TABLE 60 FRANCE PHARMACOGENOMICS MARKET, 2019 - 2025, USD MILLION

TABLE 61 FRANCE PHARMACOGENOMICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION

TABLE 62 FRANCE PHARMACOGENOMICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION

TABLE 63 FRANCE PHARMACOGENOMICS MARKET BY APPLICATION, 2015 -

2018, USD MILLION

TABLE 64 FRANCE PHARMACOGENOMICS MARKET BY APPLICATION, 2019 - 2025, USD MILLION

TABLE 65 FRANCE PHARMACOGENOMICS MARKET BY END USER, 2015 - 2018, USD MILLION

TABLE 66 FRANCE PHARMACOGENOMICS MARKET BY END USER, 2019 - 2025, USD MILLION

TABLE 67 RUSSIA PHARMACOGENOMICS MARKET, 2015 - 2018, USD MILLION

TABLE 68 RUSSIA PHARMACOGENOMICS MARKET, 2019 - 2025, USD MILLION

TABLE 69 RUSSIA PHARMACOGENOMICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION

TABLE 70 RUSSIA PHARMACOGENOMICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION

TABLE 71 RUSSIA PHARMACOGENOMICS MARKET BY APPLICATION, 2015 - 2018, USD MILLION

TABLE 72 RUSSIA PHARMACOGENOMICS MARKET BY APPLICATION, 2019 - 2025, USD MILLION

TABLE 73 RUSSIA PHARMACOGENOMICS MARKET BY END USER, 2015 - 2018, USD MILLION

TABLE 74 RUSSIA PHARMACOGENOMICS MARKET BY END USER, 2019 - 2025, USD MILLION

TABLE 75 SPAIN PHARMACOGENOMICS MARKET, 2015 - 2018, USD MILLION

TABLE 76 SPAIN PHARMACOGENOMICS MARKET, 2019 - 2025, USD MILLION

TABLE 77 SPAIN PHARMACOGENOMICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION

TABLE 78 SPAIN PHARMACOGENOMICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION

TABLE 79 SPAIN PHARMACOGENOMICS MARKET BY APPLICATION, 2015 - 2018, USD MILLION

TABLE 80 SPAIN PHARMACOGENOMICS MARKET BY APPLICATION, 2019 - 2025, USD MILLION

TABLE 81 SPAIN PHARMACOGENOMICS MARKET BY END USER, 2015 - 2018, USD MILLION

TABLE 82 SPAIN PHARMACOGENOMICS MARKET BY END USER, 2019 - 2025, USD MILLION

TABLE 83 ITALY PHARMACOGENOMICS MARKET, 2015 - 2018, USD MILLION

TABLE 84 ITALY PHARMACOGENOMICS MARKET, 2019 - 2025, USD MILLION

TABLE 85 ITALY PHARMACOGENOMICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION

TABLE 86 ITALY PHARMACOGENOMICS MARKET BY TECHNOLOGY, 2019 - 2025,
USD MILLION

TABLE 87 ITALY PHARMACOGENOMICS MARKET BY APPLICATION, 2015 - 2018,
USD MILLION

TABLE 88 ITALY PHARMACOGENOMICS MARKET BY APPLICATION, 2019 - 2025,
USD MILLION

TABLE 89 ITALY PHARMACOGENOMICS MARKET BY END USER, 2015 - 2018,
USD MILLION

TABLE 90 ITALY PHARMACOGENOMICS MARKET BY END USER, 2019 - 2025,
USD MILLION

TABLE 91 REST OF EUROPE PHARMACOGENOMICS MARKET, 2015 - 2018, USD
MILLION

TABLE 92 REST OF EUROPE PHARMACOGENOMICS MARKET, 2019 - 2025, USD
MILLION

TABLE 93 REST OF EUROPE PHARMACOGENOMICS MARKET BY TECHNOLOGY,
2015 - 2018, USD MILLION

TABLE 94 REST OF EUROPE PHARMACOGENOMICS MARKET BY TECHNOLOGY,
2019 - 2025, USD MILLION

TABLE 95 REST OF EUROPE PHARMACOGENOMICS MARKET BY APPLICATION,
2015 - 2018, USD MILLION

TABLE 96 REST OF EUROPE PHARMACOGENOMICS MARKET BY APPLICATION,
2019 - 2025, USD MILLION

TABLE 97 REST OF EUROPE PHARMACOGENOMICS MARKET BY END USER,
2015 - 2018, USD MILLION

TABLE 98 REST OF EUROPE PHARMACOGENOMICS MARKET BY END USER,
2019 - 2025, USD MILLION

TABLE 99 KEY INFORMATION – ABBOTT LABORATORIES

TABLE 100 KEY INFORMATION - EMPIRE GENOMICS LLC

TABLE 101 KEY INFORMATION – ILLUMINA, INC.

TABLE 102 KEY INFORMATION – ONEOME LLC

TABLE 103 KEY INFORMATION – MYRIAD GENETICS INC.

TABLE 104 KEY INFORMATION – THERMO FISHER SCIENTIFIC, INC.

TABLE 105 KEY INFORMATION – TEVA PHARMACEUTICALS INDUSTRIES LTD.

TABLE 106 KEY INFORMATION – BAYER AG

TABLE 107 KEY INFORMATION – OPKO HEALTH, INC.

TABLE 108 KEY INFORMATION – BECTON, DICKINSON AND COMPANY

List Of Figures

LIST OF FIGURES

FIG 1 METHODOLOGY FOR THE RESEARCH

FIG 2 SWOT ANALYSIS: ABBOTT LABORATORIES

FIG 3 SWOT ANALYSIS: THERMO FISHER SCIENTIFIC, INC.

FIG 4 SWOT ANALYSIS: BAYER AG

FIG 5 SWOT ANALYSIS: BECTON, DICKINSON AND COMPANY

I would like to order

Product name: Europe Pharmacogenomics Market (2019-2025)

Product link: <https://marketpublishers.com/r/EA9F8A93B28EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/EA9F8A93B28EN.html>